1. EXPEDITED PROTOCOL REVIEW AN IRB INFOSHORT APRIL 2013

2. EXPEDITED DEFINITION Expedited review studies are those minimal risk protocols that do not need to be reviewed by the fully convened IRB (21 CFR 56.110; 45 CFR 46.110) *They constitute 75% of the Yale biomedical IRB workload; majority are amendments to approved protocols *New studies are usually submitted on a full IRB application; MRR application specially created *The approval criteria are the same as for the full convened meeting *The expedited reviewer can approve, SMR, or defer approval but cannot disapprove (full board action only)

3. WHO REVIEWS? Expedited review may be conducted by the following individuals : An IRB Chair An experienced IRB member designated by the Chair A regulatory analyst (IRB staff) who also serves as an IRB member designated by the Chair

4. EXPEDITED REVIEW CATEGORIES Federal regulations specify : *The overall protocol must be minimal risk to even be considered for expedited review* 1. Research on drugs or devices for which an investigational new drug or investigational device exemption is not required (e.g., approved drug; non-significant risk device) 2. Collection of blood samples from healthy individuals (limit on amount and frequency of blood drawn) 3. Prospective collection of biological specimens by non-invasive means (examples given) 4. Collection of data using non-invasive procedures routinely employed in clinical practice 5. Research involving materials (data, records, etc.) that have been collected or will be collected solely for non-research purposes. 6. Collection of data from voice, video, digital or image recordings made for research purposes

5. EXPEDITED REVIEW CATEGORIES-2 7. Research on individual or group characteristics or behavior (such as cultural beliefs, perception, language) or research employing survey, oral history, program evaluation 8. Continuing review of research previously approved by the convened IRB, limited to the following: Research is permanently closed to enrollment, all subjects have completed all research interventions and the study is active only for long-term follow-up Research where no participants have been enrolled and no added risks have been identified Research where the remaining research activity is limited to data analysis 9. Continuing review of research not conducted under an investigational new drug application or investigational device exemption where the research does not other wise qualify for expedited BUT the IRB has determined and documented at a convened meeting that the research involves no greater than minimal risk and no additional risks have been identified.

6. RELATIONSHIP TO THE CONVENED MEETING Federal regulations require IRB members be informed of research proposals that have been approved under the expedited process. Every meeting agenda includes a list of the expedited IRB review determinations that have been made in the previous week. This includes those that have undergone expedited review and those that were determined to be exempt.

7. ADDITIONAL INFORMATION See our website at http://www.yale.edu/hrpp/policies/index.html#IRBReview Policy 100: Institutional Review Board (IRB) Review of Research Protocols Involving Human ParticipantsInstitutional Review Board (IRB) Review of Research Protocols Involving Human Participants Procedure 100 PR2: Expedited ReviewExpedited Review